Abstract
Metadichol® a nano formulation of long-chain lipid alcohols derived from food. It is an inverse agonist of Vitamin D Receptor (VDR), Aryl Hydrocarbon Receptor (AHR), and Ror Game (RORC) that could have beneficial effects on skin diseases. We now present case studies of patents with various skin disease show Metadichol is an inverse agonist of these nuclear receptors thus modulating Th1 pathway towards a TH2 and Th 17 and IL 17 and IL22 and also being a TNF alpha inhibitor can modulate IL23 thus blocking the major pathways that exacerbate many Skin diseases. Metadichol is the first molecule successfully navigates around the problems involved with promiscuous ligands and targets. It fulfils the goals of the emerging field of Poly pharmacology, i.e. a single drug is able to bind to multiple targets beyond the “one drug, one target” philosophy. We show how Metadichol is an innovative treatment for treating multiple skin diseases eczema, acne, diabetic wounds and viral and bacterial infection and also improving skin texture. Metadichol® is a safe nontoxic low cost solution and is an alternative to numerous clinical candidates in combating over 3000 skin diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Clinical & Experimental Dermatology Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
